Radiology

Guest: Jimmy T. Lee, MD

Guest: Arlene B. Chapman, MD

This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Nadia N. Laack, MD

As survival for patients with pediatric brain tumors improves, reducing the long-term effects of cancer treatment is increasingly important. Fortunately, proton radiotherapy along with several other advancements are helping us achieve that goal. Here to share the latest treatments for pediatric patients with brain tumors with Dr. Charles Turck is pediatric oncology physician Dr. Nadia Laack.

For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.

Host: Peter Buch, MD, FACG, AGAF, FACP

Guest: Rajeev Attam, MD

Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterologist Dr. Rajeev Attam.

Host: Jacob Sands, MD

Guest: Aaron S. Mansfield, MD

There are different treatment options available for early-stage mesothelioma, and there seem to be differences in standard practice from one center to the next. Joining Dr. Jacob Sands to share how he approaches the treatment of early-stage mesothelioma using the latest options is Dr. Aaron Mansfield, an Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.

Host: Jacob Sands, MD

Guest: Aaron S. Mansfield, MD

Mesothelioma is a cancer with limited treatment options, so how can we manage it in the first and second-line settings and beyond? Here with Dr. Jacob Sands to walk us through the various treatment approaches to mesothelioma is Dr. Aaron Mansfield, Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.

Guest: Gregory J Kubicek, MD

When caring for patients who are at greater risk of complications from COVID-19, what extra precautions are needed to help keep them safe and healthy? That’s what staff radiation oncologist Dr. Gregory Kubicek from the MD Anderson Cooper Cancer Center shares with us.

Published June 23, 2020

Guest: Bret Nelson, MD

When it comes to using ultrasound at the point of care in the setting of COVID-19, what do we need to keep in mind? Here to share his five key considerations is Dr. Bret Nelson, Professor of Emergency Medicine and the Chief of the Emergency Medicine Ultrasound Division at Mount Sinai Hospital.

Published June 5, 2020

Host: Matt Birnholz, MD

Guest: Wes Ely, MD, MPH

After surviving a critical illness, many patients look forward to their lives returning to normal, but unfortunately, that’s not always possible.

To uncover the far-reaching impacts of delirium, Dr. Matt Birnholz is joined by Dr. Wes Ely, Professor of Medicine and Co-Director of the Center for Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University’s School of Medicine which focuses on improving the lives and care of patients in the intensive care unit to ensure both physical and cognitive rehabilitation.

Host: Shira Johnson, MD

Guest: Ronald DeMatteo, MD, FACS

A Gastrointestinal Stromal Tumor (GIST) is a rare sarcoma that begins in the digestive tract or stomach, with an incident rate in the United States of approximately 4,000 to 6,000 cases per year. Since these tumors behave differently from other gastrointestinal cancers, they require a specialized treatment plan.

Host Dr. Shira Johnson chats with Ronald DeMatteo, MD, FACS, Chair of the Department of Surgery and a surgical oncologist at Penn Medicine. They discuss the diagnosis, treatment and current clinical research of GIST. Dr. DeMatteo is a world-renowned surgical expert and researcher for the rare GIST. His research breakthroughs helped develop the new standard of care for GIST.

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.

Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.

A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety.

Released 12/19/2017